AHA 2022 Conference Coverage


 

AHA 2022: Long-Term Efficacy and Safety of Inclisiran in Patients With High Cardiovascular Risk and Elevated Low-Density Lipoprotein Cholesterol (ORION-3)

10,768 views
November 30, 2022
Comments 7
Login to view comments. Click here to Login